This study is looking at a new way to screen for diabetes after pregnancy in women who had gestational diabetes (diabetes during pregnancy). Currently, a test called an Oral Glucose Tolerance Test (OGTT) is used, but many women find it difficult to complete. This study will offer a Continuous Glucose Monitor (CGM) called the Freestyle LibrePro by Abbott for 14 days as an alternative. We want to see if using CGM, which is a low-burden and remote way to check blood sugar, can encourage more women to get screened. You may be able to join if you are 12-16 weeks postpartum, had gestational diabetes in your most recent pregnancy, and have an OGTT ordered. The main goal is to see how many eligible patients choose to use the CGM for screening. This study is currently recruiting up to 1300 participants.

Study design

This is an interventional study that plans to enroll up to 1300 women. It is testing a new screening method against the current standard.

What's involved

You would use a Continuous Glucose Monitor (CGM) for 14 days. This would be done remotely.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Continuous Glucose Monitor (CGM) uptake, is measured at 20 weeks postpartum.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.